# BPC-157: Research Overview — aminopeptides.co > A literature summary of BPC-157 (Body Protection Compound 157): angiogenesis mechanism, rodent healing studies, pharmacokinetics, reported effects, and regulatory status. Research Peptide Fundamentals. Body Protection Compound 157 — a stable gastric pentadecapeptide whose repair effects in animal models track most consistently with the growth of new blood vessels into damaged tissue. ## The short version **BPC-157** stands for Body Protection Compound 157. It is a fifteen-amino-acid synthetic peptide copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly rats — it appears to speed healing in tendon, gut, muscle, and nerve. The most consistent explanation in the literature is that it stimulates new blood-vessel growth into injured tissue, which restores the oxygen and nutrients that repair needs [4]. The honest line: almost everything known about BPC-157 comes from animals. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous controlled trials [2]. BPC-157 is not approved as a medicine anywhere. It is banned in sport. Common online claims about weight loss, muscle building, and testosterone are not supported by the published science and should be treated skeptically [2]. This page summarizes what was studied. It is not advice and lists no human dose. ## What it is BPC-157 is classified as a *stable gastric pentadecapeptide*. "Pentadecapeptide" means a fifteen-amino-acid chain; "stable gastric" because it is derived from a cytoprotective protein in gastric juice and resists breakdown there. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It carries research designations PL 14736, PLD-116, PL-10, and PL-10. Molecular formula: C62H98N16O22. It is a synthetic compound — not extracted from any natural source — and it is not an approved drug. Pharmacokinetic work in rats and dogs characterized it as having a short elimination half-life (under 30 minutes), modest intramuscular bioavailability (approximately 14-19% in rats, 45-51% in dogs), and rapid metabolism into small peptide fragments that re-enter normal amino-acid pathways [3]. The intact peptide does not linger in the bloodstream. ## How it works The best-characterized pathway is *angiogenesis* — new blood-vessel growth. In a 2017 study spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells, BPC-157 up-regulated the expression of VEGFR2 (a key vessel-growth receptor) and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS signaling pathway; blocking endocytosis blocked the effect [4]. Blood-flow recovery in an ischemic muscle model was accelerated [4]. Additional reported pathways include: - **FAK-paxillin complex** — a cell-migration route that helps cells move into a wound site - **Growth hormone receptor sensitization** in tendon fibroblast cells - **Nitric-oxide system modulation** — connected to the VEGFR2-eNOS arm above - **Neurotransmitter system effects** — serotonin and dopamine modulation noted in preclinical work The peptide does not appear to hit a single target. Its animal-model effects span several repair-related pathways, with the angiogenesis story most consistently supported by independent data [4]. ## What the research shows **Gastric cytoprotection.** The original rationale for BPC-157 was gut protection. In Wistar rats, it reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric; ulcer-formation inhibition ratios ran roughly 46-66% at higher doses, with accelerated epithelial rebuilding and granulation-tissue formation [5]. **Angiogenesis mechanism.** The 2017 work by Hsieh et al. established the VEGFR2-Akt-eNOS pathway as the primary vascular mechanism in endothelial cell culture, chick membrane, and rat ischemia models [4]. This is the most independently replicated mechanistic finding. **Pharmacokinetics.** The first formal ADME characterization (rats and beagle dogs, 2022) found linear pharmacokinetics, a very short elimination half-life, modest IM bioavailability, and rapid breakdown to peptide fragments entering amino-acid metabolism [3]. These data help model tissue exposure but do not establish human dosing. **Human evidence.** A 2025 first-in-human intravenous safety pilot administered BPC-157 up to 20 mg to two healthy adults; no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two people — a safety signal, not an efficacy finding. A 2025 narrative review counts only three pilot studies total, confirms no rigorous large-scale controlled trials exist, and recommends treating BPC-157 as investigational with caution [2]. ## Reported effects, cautions & safety The safety picture in the thin human dataset and the animal record is generally reassuring — but "as far as it goes" is the key phrase. Long-term, large-sample human safety data do not exist, so the true benefit-risk balance in people is unknown [2]. **Community-reported effects (anecdotal, not clinical evidence):** In research-use communities, BPC-157 is tried most often for stubborn tendon, ligament, and joint injuries. Very commonly reported benefits include faster recovery from those injuries and reduced joint stiffness. Frequently reported: improved digestive or gut symptoms, reduced bloating and cramping. Occasionally reported benefits include faster skin and wound healing, and improved sleep or mood — though commentators note the last two could easily reflect less pain or gut discomfort rather than a direct effect. Very commonly reported adverse effects include brief injection-site stinging and a small redness or bump. Frequently reported: mild nausea or loose stools, especially in the first few days. Occasionally reported: mild fatigue in the first week, headache, dizziness shortly after injecting, and transient flushing. Rarely: heart palpitations, which commentators recommend investigating promptly. All of these are anecdotal, unverified self-reports from research-use communities — not findings from controlled clinical studies. **Cautions from the literature:** - *Single-group dominance.* A large share of the foundational BPC-157 literature originates from one research group. Newer reviewers explicitly flag limited independent replication [2]. - *Pro-angiogenic mechanism.* Because the peptide's repair effects are tied to vessel growth via VEGFR2, there is a theoretical concern for individuals with active or suspected cancers, which also depend on angiogenesis for growth — though this is mechanistic reasoning, not a human finding [4]. - *Serotonin interactions.* Preclinical work shows BPC-157 alters brain serotonin activity; there is a theoretical, animal-based concern about combining it with serotonin-raising medicines. - *Banned in sport.* WADA prohibits BPC-157 at all times under the S0 non-approved substances category. - *Unregulated supply.* Not an approved drug; sold for laboratory research use only. Identity and purity of any given product are unverified outside formal study conditions. ## Where it fits in repair and metabolic research Among this desk's three compounds, BPC-157 occupies the *tissue repair* end of the spectrum. Its animal evidence spans tendon, gut, muscle, and nerve, unified by the angiogenesis mechanism. Its evidence base is the widest preclinically but thinnest in humans — three small pilots, no large trials [2]. Read alongside [retatrutide](/retatrutide), which addresses metabolic function via three receptor systems simultaneously, and [tesamorelin](/tesamorelin), which carries the only regulatory approval across the three, BPC-157 represents the preclinical frontier of this field: a strong and consistent animal signal that has barely entered controlled human study. See the [comparison page](/compare) for a side-by-side view. --- An austere digest of published research — mechanism, species, and outcome, exactly as the literature reports them.